depression
DEPRESSION

Depression is a mood disorder wherein the patient have a pervasive sad mood or loss of interest in most activities for at least 2 weeks.

It can cause significant distress & impairment. It is also a chronic, episodic and relapsing syndrome.

Treatment can either be by psychotherapy alone or pharmacotherapy alone or psychotherapy combined with pharmacological therapy.

Depression Management

Follow Up

 Follow-up After Acute Phase Treatment

  • Provide frequent follow-up during the 1st 2-4 months of therapy until remission occurs (acute phase)
    • Monitor for adverse drug effects, response to therapy
    • Assess degree of danger to self or others
    • Monitor symptomatic and functional status
    • Follow for switch to mania
  • Re-assess therapy after 4-8 weeks
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
20 Jun 2020
The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illnesses. The second day of the symposiumaddressed the topic of schizophrenia management, focusing on treatment goals, the rationale forpartial dopamine D(2) receptor agonism and the use of long-acting injectable (LAI) antipsychotics topromote adherence.
Pearl Toh, 4 days ago
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
3 days ago
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Christina Lau, Yesterday

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.